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Abstract 1 
Electronic medical records from first opinion equine veterinary practice may represent a unique 2 
resource for epidemiologic research.  The appropriateness of this resource for risk factor analyses 3 
was explored as part of an investigation into clinical and pharmacologic risk factors for laminitis.  4 
Amalgamated medical records from seven UK practices were subjected to text mining to identify 5 
laminitis episodes, systemic or intra-synovial corticosteroid prescription, diseases known to affect 6 
laminitis risk and clinical signs or syndromes likely to lead to corticosteroid use.  Cox proportional 7 
hazard models and Prentice, Williams, Peterson models for repeated events were used to estimate 8 
associations with time to first, or subsequent laminitis episodes, respectively.  Over seventy percent 9 
of horses that were diagnosed with laminitis suffered at least one recurrence.  Risk factors for first 10 
and subsequent laminitis episodes were found to vary.  Corticosteroid use (prednisolone only) was 11 
only significantly associated with subsequent, and not initial laminitis episodes.  Electronic medical 12 
record use for such analyses is plausible and offers important advantages over more traditional data 13 
sources.  It does, however, pose challenges and limitations that must be taken into account, and 14 
requires a conceptual change to disease diagnosis which should be considered carefully. 15 
 16 
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1. Introduction 25 
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Laminitis is a painful, prevalent, multifactorial condition of ungulates.  In the domestic horse, 26 
compromised welfare due to the pain and immobility associated with laminitis often leads to 27 
euthanasia(Slater, 2014; C. E. Wylie et al., 2013; Claire E Wylie et al., 2013).  Many studies have 28 
identified significant risk factors for laminitis, but have not always been in agreement (Hunt, 1993; 29 
Polzer and Slater, 1997; Slater et al., 1995; C. E. Wylie et al., 2013).  Administration of certain 30 
systemic corticosteroids has been presumed to pose a risk of laminitis, but this potentially putative 31 
risk factor has not been well studied in the general horse population (Bailey and Elliott, 2007; Bailey, 32 
2010; French et al., 2000; Katz and Bailey, 2012; McCluskey and Kavenagh, 2004).  Given financial 33 
constraints and ethical implications, previous studies have often been of limited sample size, thus 34 
reducing the power of the analyses to detect significant relationships of small effect size.  In 35 
addition, the recurrent nature of laminitis has not been fully taken into account.  It is possible that 36 
the initial case of laminitis is associated with different risk factors compared to subsequent episodes.   37 
 38 
The use of electronic medical records (EMR) in first-opinion equine veterinary medicine in the UK is 39 
widespread.  Although amalgamation of records between practices for epidemiologic research 40 
purposes is somewhat rare at present, sharing of such data will become more common in future 41 
(Johns and Adams, 2015; Wylie et al., 2014).  This resource can offer huge sample sizes, and could be 42 
more easily extrapolated to the general horse population compared with other study types.  It may, 43 
however, suffer from problems not usually encountered in prospective studies, due to record 44 
accuracy and completeness, for example.  In first-opinion practice, diagnoses and case management 45 
decisions are often informed by less than the full battery of gold-standard tests available for each 46 
condition.  Indeed, veterinarians in practice are often required to treat horses according to tentative 47 
diagnoses reached by pattern recognition alone, or with minimal investigation, due to financial, 48 
time, or practical constraints.  In addition, free-text medical records vary greatly in verbosity 49 
between individuals, cases and practices.  EMR offer a true historical account of the decisions made 50 
in the treatment of individual animals, whether those decisions were well-founded or otherwise.  As 51 
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such, EMR are a very different data-type compared with experimental data, where exhaustive 52 
exclusion criteria can be universally applied.  EMR likely contain a wealth of useful, accurate 53 
information, but may require a lower sensitivity of case identification to be of use. 54 
 55 
The aims of this study were to use a large database of first-opinion electronic medical records to 56 
analyse the relationships between known medical risk factors for the first, and subsequent episodes 57 
of laminitis.  Our hypotheses were that a) systemic corticosteroid administration is significantly and 58 
independently associated with laminitis risk, and b) significant risk factors for initial and subsequent 59 
laminitis episodes will vary. 60 
 61 
Ethical approval for this study was granted by the Research Ethics Committee, School of Veterinary 62 
Medicine, University of Glasgow. 63 
 64 
2. Materials and Methods 65 
2.1 Data source 66 
EMR from a convenience sample of seven first-opinion equine veterinary practices around the UK 67 
were collected and amalgamated into a single anonymised dataset (Table 1).  These data spanned 68 
twenty-six years (1987 to 2013, n=70481 records), and contained the following database; unique 69 
numeric identifier per horse, date of birth, date of entry into the system (date of veterinary record), 70 
breed and sex.  Free-text notes detailing the reason for the consultation, clinical findings, 71 
presumptive or definitive diagnosis, treatment, and prescription information were available for each 72 
record.  Age was calculated as the date of record minus the date of birth, and ages less than 0 or 73 
greater than 40 years (due to erroneous date records in 16% of records) were removed.  Age was 74 
subsequently categorised as follows: under 1 year, 1 to 4 years, 4 to 8 years, 8 to 13 years and above 75 
13 years.  Sex was converted in to three categories: female, male, and unknown sex.  Breeds were 76 
converted initially into ten categories; Arab/Arab cross, Cob/Cob cross, Draught/Draught cross, 77 
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Native/Native cross, pony/pony cross, Thoroughbred/Thoroughbred cross, Warmblood/Warmblood 78 
cross, Welsh/Welsh cross, unknown and other breed.  Horses were followed from their first record 79 
in the dataset, to their first or subsequent laminitis episodes, or until they died, were lost from 80 
follow up or the study period ended.  Censoring was assumed to be uninformative.  All analyses 81 
were conducted in R statistical environment (R Core Team, 2015).  Statistical significance was set at 82 
0.05 and all testing was two-tailed. 83 
 84 
2.2 Text Mining 85 
Text mining was employed to convert free text records into numeric variables.  Commercially 86 
available text mining software (SimStat and WordStat, Provalis Research Ltd., Canada) was used to 87 
construct dictionaries of words or phrases designed to mine free text records for instances of 88 
systemic or intra-synovial corticosteroid administration (triamcinolone acetonide, dexamethasone, 89 
prednisolone and methylprednisolone) and laminitis, and for records of syndromes known to be 90 
related to laminitis, or known to be a common indication for systemic or intra-synovial corticosteroid 91 
use (Table 2).  These syndromes were decided upon a priori after discussion with experienced 92 
equine veterinarians, and examination of a proportion of EMR containing corticosteroid 93 
administration.  The iterative mining process used was similar to that published in Lam et al. 2007, 94 
and validated for use in veterinary data by Anholt et al.(R M Anholt et al., 2014; Lam et al., 2007).  95 
Negated terms were excluded where possible (e.g. ‘not Cushing’s disease’).   A ‘case’ of laminitis or 96 
disease was thereby defined as a record containing at least one non-negative word or phrase 97 
pertaining to that condition.  98 
 99 
2.3 Outcomes 100 
Two outcomes were assessed in this study, thus two models were built.  The first episode of laminitis 101 
per horse was the initial outcome examined (Model 1).  Subsequent episodes of laminitis were 102 
examined as a secondary outcome (Model 2).  Horses were at risk of a subsequent episode of 103 
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laminitis 60 days following the previous episode.  A hypothesised causal web for the association of 104 
all factors involved in these analyses is shown in Figure 1. 105 
 106 
Figure 1. Proposed causal web: possible relationships between reasons for corticosteroid 107 
administration, chronic diseases and laminitis. 108 
 109 
2.4 Survival analyses 110 
2.4.1 First laminitis episode (Model 1) 111 
Univariable Cox proportional hazard models were used to estimate the association between horse 112 
characteristics, disease and corticosteroid administration, and time to first laminitis episode.  A 113 
random (frailty) effect was included to account for clustering within practices, and models were 114 
stratified according to age group at the time of entry to the dataset.  Variables were retained for 115 
consideration if the Wald p-value for the coefficient was < 0.2.  The assumption of proportional 116 
hazards was tested for each variable by visual inspection of scaled Schoenfeld residuals plots.  The 117 
breed variable was re-categorised to leave only statistically significant levels, with others subsumed 118 
into the ‘Unknown/other breed’ category. Collinearity between potential risk factors was assessed 119 
with Cramer’s V, and where associations exceeded 0.4, the variable with the higher univariable AIC 120 
was considered for exclusion from further analyses (Rosner and Rosner, 2006). 121 
 122 
A forward stepwise manual multivariable model-building procedure was then carried out, by 123 
sequential inclusion of significant variables in order of ascending AIC.  Variables were retained if 124 
coefficient Wald p-values or the likelihood ratio test (LRT) p-value for inclusion of the variable was < 125 
0.05.  All pairwise interactions between retained variables were assessed for LRT significance, and 126 
were included in the final model in order of ascending AIC.  Variables not included were 127 
subsequently forced back into the model to assess the proportion change in existing coefficients.  128 
Variables were considered for retention if they led to a change in any existing coefficients of more 129 
than 30%.  The power of the model to detect a postulated hazard ratio of 1.3 for the effect of 130 
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corticosteroid prescription (excluding methylprednisolone) on laminitis risk at significance level 0.05 131 
was 81%, 96% and 64% for triamcinolone, dexamethasone and prednisolone, respectively. 132 
 133 
2.4.2 Subsequent laminitis episodes (Model 2) 134 
To investigate the secondary outcome, only 46 horses had more than 6 episodes of laminitis, so 135 
analysis of subsequent laminitis episodes was restricted to the second to sixth episodes (n=37888 136 
records, 3358 horses).  Recurrent airway obstruction (RAO), pituitary pars intermedia dysfunction 137 
(PPID) and equine metabolic syndrome (EMS) were considered lifelong risk factors for laminitis, 138 
therefore all time-points following detection of these conditions in an individual were considered 139 
positive for that condition, irrespective of future diagnoses.  For analysis of the time to subsequent 140 
laminitis episode (second to sixth), a recurrent-events extension to the Cox proportional hazards 141 
model was employed.  The Prentice, Williams, Peterson (PWP) model allows for ordered recurrent 142 
events, and adjusts for clustering and the non-independence of events within individuals(Prentice et 143 
al., 1981).  A frailty term was included to account for clustering within practices, and models were 144 
stratified by age group.  Univariable and multivariable model building procedures proceeded as 145 
above.  Proportional hazards assumptions for three syndromes were violated; the risk of time to 146 
subsequent laminitis episode of PPID, colic and dermatologic syndromes was not static over time 147 
(and tended to increase in all cases), therefore interaction terms with time were added to account 148 
for these time-varying covariates. 149 
 150 
Table 1. Description of the convenience sample of first-opinion equine veterinary practices 151 
throughout the UK that contributed data to the current study between 1987 to 2013. 152 
Practice 
Number of 
full time 
veterinarians 
Location 
Cover 
own 
out-of-
RCVS 
Accredited* 
Species 
seen 
Number 
of 
branches 
Number 
of 
records 
7 
 
hours 
1 11 Scotland Yes Yes Mixed 2 2893 
2 21 
Central 
England 
Yes Yes 
Equine 
only 
1 38705 
3 17 
Northern 
England 
Yes Yes Mixed 5 1442 
4 14 
Central 
England 
Yes No Mixed 4 14339 
5 11 
Southern 
England 
Yes No 
Equine 
only 
1 5565 
6 4 
Northern 
England 
Yes Yes 
Large 
species 
1 5052 
7 8 
Northern 
England 
Yes No Mixed 2 2485 
*Accreditation of the practice by the Royal College of Veterinary Surgeons, URL: 153 
http://www.rcvs.org.uk/practice-standards-scheme/. 154 
 155 
Table 2. Examples of the words and phrases used to categorise electronic medical records (EMR) 156 
from a convenience-sampled UK horse cohort between 1987 and 2013.  Where possible common 157 
negations were excluded, and all terms were validated through assessment of the term in context. 158 
Category Examples of words/phrases used for case detection (excluding misspellings) 
Laminitis Laminitis, founder, laminitic 
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Triamcinolone Adcortyl, Triamcinolone, Kenalog, Vetalog 
Recurrent Airway 
Obstruction (RAO) 
RAO, heaves, Chronic Obstructive Pulmonary Disease (COPD) 
Respiratory Bronchospasm, bronchoconstriction, cough, dyspnoea, pneumonia, wheeze 
Dermatologic 
Abrasion, alopecia, blepharitis, bursitis, cellulitis, Chorioptes, dermatitis, 
eczema, folliculitis, furunculosis, lymphangitis, pyoderma, sweet itch, 
thrombophlebitis 
Equine Metabolic 
Syndrome (EMS) 
EMS, metabolic syndrome, peripheral Cushing’s 
Pituitary Pars 
Intermedia 
Dysfunction (PPID) 
Cushing’s disease, PPID, hyperadrenocorticism, Pergolide, Prascend 
Prednisolone Prednicare, Prednidale, Prednisolone, Preds 
Methylprednisolone Depomedrone, Methylprednisolone 
Dexamethasone Colvasone, Dexamethasone, Dexadresson, Dexafort, Duphacort 
Gastrointestinal Colic, colitis, diarrhoea, enteritis, enterocolitis, scour 
Systemic 
Abortion, allergy, anaphylaxis, autoimmune, bacteraemia, dystocia, 
endometritis, endotoxaemia, hepatitis, mastitis, Pemphigus, peritonitis, 
placentitis, pyelonephritis, pyrexia, sepsis, toxaemia, urticaria, vasculitis 
Orthopaedic 
Osteoarthritis, epiphysitis, kissing spines, osteomyelitis, sesamoiditis, spavin, 
spondylosis, tendonitis 
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Neurological Ataxia, encephalopathy, hemiplegia, meningitis, Wobblers syndrome 
 159 
3. Results 160 
3.1 Population characteristics 161 
Table 3 reports the variables considered for models of association with time to laminitis episode.  162 
Dexamethasone was the corticosteroid prescribed to the greatest number of horses (2204, 3.1%), 163 
and gastrointestinal syndromes affected the largest number of horses of all the disease syndromes 164 
studied (7760, 11%).  Laminitis was detected in medical records of 4081 (5.8%) horses (Table 4).  Of 165 
these, 72% (2965 horses) had more than one laminitis episode.  The median (IQR) time between first 166 
and second episodes of laminitis was 363 days (133 – 865).  Table 5 gives a description of the 167 
outcomes tested, including their event rates.   168 
 169 
Table 3. Baseline characteristics of a convenience sample of UK horses attended by seven first-170 
opinion UK veterinary practices between 1987 and 2013.  171 
Characteristic  
Number of 
horses 
Percentage 
(n=70481) 
Number of 
laminitis-
positive 
horses (%) 
Sex Female 26019 36.9 1682 (6.4) 
 Male 37975 53.9 2101 (5.5) 
 Unknown 6487 9.2 298 (4.6) 
Practice 1 2893 4.1 168 (5.8) 
 2 38705 54.9 2681 (6.9) 
10 
 
 3 1442 2.0 82 (5.7) 
 4 14339 20.3 261 (1.8) 
 5 5565 7.9 296 (5.3) 
 6 5052 7.2 417 (8.3)  
 7 2485 3.5 176 (7.1) 
Breed Other/unknown 59681 84.7 3854 (6.5) 
 Arab 954 1.4 65 (6.8) 
 Cob 2132 3.0 110 (5.2) 
 Draught 1049 1.5 38 (3.6) 
 Native 2218 3.1 227 (10.2) 
 Pony 1415 2.0 115 (8.1) 
 Welsh 3032 4.3 305 (10.1) 
Corticosteroids  Triamcinolone 1234 1.8 38 (3.1) 
 Dexamethasone 2204 3.1 90 (4.1) 
 Methylprednisolone 306 0.4 11 (3.6) 
 Prednisolone 895 1.3 108 (12.1) 
Disease syndrome Gastrointestinal 7760 11.0 450 (5.8) 
 
Equine Metabolic 
Syndrome 
143 0.2 
82 (57.3) 
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Pituitary Pars 
Intermedia 
Dysfunction 
2070 2.9 
601 (29.0) 
 
Recurrent Airway 
Obstruction 
1228 1.7 
65 (5.3) 
 Respiratory 3773 5.4 243 (6.4) 
 Orthopaedic 1839 2.6 193 (10.5) 
 Neurological 631 0.9 65 (10.3) 
 Dermatologic 4473 6.3 323 (7.2) 
 Systemic 2778 3.9 251 (9.0)  
 172 
 173 
Table 4. Number of laminitis episodes recorded per horse between 1987 and 2013 at a convenience 174 
sample of seven UK first-opinion equine veterinary practices. 175 
Total number of laminitis 
episodes 
Number of horses 
Percentage of horses 
(n=70481) 
0 66400 94.21 
1 1116 1.58 
2 2553 3.62 
3 79 0.11 
4 208 0.30 
12 
 
5 30 0.04 
6 49 0.07 
7 8 0.01 
8 21 0.03 
9 4 0.01 
10 3 <0.01 
11 1 <0.01 
12 3 <0.01 
13 1 <0.01 
14 1 <0.01 
15 1 <0.01 
16 1 <0.01 
17 0 0 
18 1 <0.01 
19 0 0 
20 1 <0.01 
 176 
 177 
Table 5. Description of the outcomes assessed in the current study of first and subsequent laminitis 178 
episodes in a UK horse cohort between 1987 and 2013. 179 
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Outcome 
Number of 
horses (%) 
Number of 
events 
Range of 
events 
Median 
follow-up time 
(days) (IQR) 
Total time 
Event rate 
per 1000 
horse 
years 
(95% CI) 
First 
laminitis 
episode  
3977 (5.7) 3977 NA 
901 (84 – 
3480) 
23597.4 
years 
168.5 
(163.8 – 
173.4) 
All laminitis 
episodes 
3977 (5.7) 8168 0-20 
1188 (87 – 
4343) 
50783.2 
years 
160.8 
(157.7 – 
164.1) 
IQR Inter-quartile range; CI confidence interval. 180 
 181 
3.2 First laminitis episode (Model 1) 182 
Table 6 reports significant associations between risk factors and the time to first laminitis episode.  183 
Compared to unknown/other breeds, Arabs, cobs, Native breeds, ponies and Welsh breeds were 184 
associated with time to first laminitis episode.  Of all syndromes studied, only neurological 185 
syndromes were not associated with time to first laminitis episode.  Administration of systemic 186 
corticosteroids was not significantly associated with time to the first laminitis episode.  A number of 187 
significant interaction terms were included in the final model for first laminitis episode (see Table 6).  188 
Triamcinolone prescription was not significant in a univariable model (p-value 0.84), and no 189 
methylprednisolone was prescribed during the time from study entry to first laminitis episode for 190 
any horse.  Dexamethasone and prednisolone prescription were significant in univariable models (p-191 
values <0.01), but were dropped from the multivariable model after inclusion of disease and 192 
signalment variables.  193 
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 194 
Table 6. Association between potential risk factors and time to first laminitis episode in a veterinary-195 
attended UK horse cohort between 1987 and 2013.  Hazard ratios are derived from Model 1, a 196 
multivariable Cox survival analysis of time to first laminitis episode. 197 
Characteristic  
Number of 
horses Hazard Ratio 
95% 
Confidence 
Interval 
Wald p-value 
Breed Unknown/other 59681 1 (REF)   
 Arab 954 1.80 1.37 – 2.34 <0.01 
 Cob 2132 1.36 1.10 – 1.69 <0.01 
 Draught 1049 0.94 0.66 – 1.33 0.72 
 Native 2218 2.46 2.10 – 2.87 <0.01 
 Pony 1415 1.77 1.43 – 2.20 <0.01 
 Welsh 3032 2.56 2.23 – 2.94 <0.01 
Disease 
syndrome 
Pituitary Pars 
Intermedia 
Dysfunction 
(PPID) 
2070 
11.18 9.26 – 13.51 <0.01 
 
Equine 
Metabolic 
Syndrome 
(EMS) 
143 
8.06 5.79 – 11.20 <0.01 
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 Gastrointestinal 7760 2.57 2.22 – 2.98 <0.01 
 Orthopaedic 1839 1.85 1.59 – 2.16 <0.01 
 Dermatologic 4473 3.70 3.03 – 4.52 <0.01 
 Systemic 2778 1.35 1.19 – 1.53 <0.01 
 Respiratory 3773 1.17 1.04 – 1.32 <0.01 
 
Recurrent 
Airway 
Obstruction 
(RAO) 
1228 
1.44 1.21 – 1.70 <0.01 
Sex Female 26019 1 (REF)  <0.01 
 Male 37975 0.88 0.82 – 0.94 <0.01 
 Unknown 6487 0.65 0.55 – 0.76 <0.01 
PPID : time   0.99 0.99 – 0.99 <0.01* 
Colic : time   0.99 0.99 – 0.99 <0.01* 
Dermatologic 
: time 
 
 
0.99 0.99 – 0.99 <0.01* 
Breed : 
dermatologic 
Other/unknown 
: Dermatologic 
 
1 (REF)  <0.01* 
 
Arab: 
Dermatologic 
 
0.28 0.11 – 0.69  
 Cob :  0.51 0.27 – 0.95  
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Dermatologic 
 
Draught : 
Dermatologic 
 
0.27 0.10 – 0.78  
 
Native : 
Dermatologic 
 
0.45 0.25 – 0.82  
 
Pony : 
Dermatologic 
 
0.17 0.04 – 0.71  
 
Welsh : 
Dermatologic 
 
0.22 0.12 – 0.40  
PPID : EMS   0.35 0.21 – 0.57 <0.01* 
PPID : 
Orthopaedic 
 
 
0.51 0.35 – 0.72 <0.01* 
EMS : 
dermatologic 
 
 
0.31 0.12 – 0.78 <0.01* 
REF referent level; *p-values from likelihood-ratio tests comparing models with and without 198 
interaction term. 199 
 200 
3.3 Subsequent laminitis episodes (Model 2) 201 
Table 7 contains all variables significantly associated with the risk of second to sixth laminitis episode 202 
in a multivariable PWP model.  Horse breed and sex were not associated with subsequent laminitis 203 
episodes.  Prednisolone prescription was associated with 5.3 times the hazard of subsequent 204 
laminitis episodes, and unlike the first laminitis episode, neurological syndromes were associated 205 
with an increased hazard also.  RAO was associated with a reduced hazard of subsequent laminitis 206 
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episodes, in contrast to its increased hazard ratio for first laminitis episode.  Methylprednisolone 207 
prescription was not associated with subsequent laminitis at the univariable stage.  All other 208 
excluded variables were significant at univariable modelling stage, then dropped at the multivariable 209 
modelling stage.  210 
 211 
Table 7. Association between risk factors and time to subsequent laminitis episode (second to sixth 212 
episodes, n=3358 horses) in horses receiving veterinary attention from a convenience sample of UK 213 
veterinary practices between 1987 and 2013. Results of Model 2, a multivariable Prentice, Williams 214 
Peterson model of time to second to sixth laminitis episode. 215 
Characteristic 
Number of Horses 
Hazard Ratio 
95% Confidence 
Interval 
Wald p-value 
Pituitary Pars 
Intermedia 
Dysfunction 
(PPID) 
721 
1.63 1.31 – 2.03 <0.01 
Orthopaedic 256 5.33 3.48 – 8.18 <0.01 
Respiratory 383 3.10 2.08 – 4.62 <0.01 
Systemic 358 2.69 1.84 – 3.93 <0.01 
Prednisolone 156 5.25 2.59 – 10.63 <0.01 
Neurological 83 7.20 3.11 – 16.67 <0.01 
Recurrent Airway 
Obstruction 
(RAO) 
294 
0.62 0.45 – 0.85 <0.01 
18 
 
PPID : Respiratory  4.53 1.50 – 13.69 <0.01* 
PPID : RAO  2.75 1.23 – 6.12 0.02* 
Systemic : RAO  7.02 1.68 – 29.38 <0.01* 
*p-values from likelihood-ratio tests comparing models with and without interaction term. 216 
 217 
4. Discussion 218 
Risk factors for the first (Model 1) and subsequent (Model 2) episodes of laminitis were found to 219 
differ in this population.  Breed, sex, EMS, colic and dermatologic syndromes were significantly 220 
associated with the first episode of laminitis, but not subsequent episodes.  Similarly, prednisolone 221 
prescription and neurological syndromes were significantly associated with subsequent laminitis 222 
episodes, but not with a horse’s first episode.  Risk factors found to affect both first, and subsequent 223 
laminitis episodes were PPID, orthopaedic, systemic, and respiratory syndromes.  Many of the 224 
clinical syndromes studied were hypothesized to only affect laminitis risk through the intermediary 225 
variable of corticosteroid prescription (Figure 1), however this was not supported by the final models 226 
reported here.  This finding may indicate that laminitis has more potential aetiological origins than 227 
first thought, and that corticosteroid use is less important. 228 
 229 
Recurrence of laminitis was common in this population, with 72% of laminitic horses experiencing at 230 
least one recurrence of the condition.  Laminitis is clinically subdivided into acute and chronic forms, 231 
the former of which can be recurrent and cause no permanent anatomic changes, and the latter of 232 
which is defined by irreversible hoof changes and worsening prognosis (Hunt, 1993; Katz and Bailey, 233 
2012; Slater et al., 1995).  Detection of these subdivisions requires radiography, and progression 234 
from acute to chronic stage occurs at unpredictable times, if at all.  In the majority of cases, the 235 
stage of laminitis was not reported in EMR, therefore this subdivision was not available for inclusion 236 
in the modelling procedures. 237 
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 238 
EMR represent an important data resource for veterinary epidemiology.  Embedded systematic 239 
clinical nomenclature systems are not yet a feature of most practice management software systems, 240 
thus all disease and treatment information (excluding auto-generated prescriptions and billing) is 241 
contained in free-text.  The largest source of error in the use of this information arises through the 242 
necessity to apply text-mining or machine learning technologies to categorise records, as manual 243 
classification would be too cumbersome and thereby negate the sample-size benefits of EMR.  244 
Record categorisation is unlikely to reach 100% sensitivity and specificity because of the variation in 245 
nomenclature, phraseology, spelling accuracy and verbosity of EMR.  However, with judicious use of 246 
powerful software, and an iterative, diligent approach, diagnostic accuracy of the text-mining 247 
process for medical data has been shown to be highly accurate, especially in the case of 248 
pharmacology(R M Anholt et al., 2014; R Michele Anholt et al., 2014; Roque et al., 2011).  The 249 
second large source of potential error in the use of EMR from first-opinion practice arises from the 250 
variable, reactive nature of primary veterinary care.  Whereas in prospective, experimental studies, 251 
inclusion criteria can and must be exhaustive, retrospective ‘real-world’ data will likely never reflect 252 
such completeness.  The role of the veterinarian is to deliver the most likely diagnosis possible, given 253 
financial and practical constraints, and to offer the most appropriate care for that individual.  In 254 
reality, diagnoses are commonly arrived at without a full, referral-level battery of appropriate tests.  255 
Treatment and management regimens vary greatly, even given seemingly identical clinical scenarios.  256 
EMR therefore represent historical accounts of the true course of clinical events, and when the 257 
general veterinary-attended population is the population of interest, study of the decisions made in 258 
the ‘real world’ may be more applicable than experimental data.  This study was based upon data 259 
from a convenience sample of practices, which may have led to a reduction in the generalizability of 260 
results, however, given that each practice offered primary care to the general horse population, this 261 
reduction should be small.   262 
 263 
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The EMR used in this study had some limitations.  In very many cases, the diagnostic criteria 264 
employed to make clinical decisions were missing, partial, or unclear.  Application of stringent 265 
diagnostic inclusion criteria was therefore not possible if the data were to be used to greatest effect.  266 
The diagnoses included in this study were therefore taken as rote, either from non-negative 267 
terminology inclusions, or prescription of medications that were very likely to indicate disease 268 
diagnosis (e.g. Pergolide use as an indicator of PPID).  In addition, many of the diseases studied are 269 
unchallenging to diagnose in a primary care setting, simply by pattern recognition of the 270 
combination of history and clinical signs presented, thus lending confidence to included diagnoses. 271 
We cannot, however be certain of the accuracy of this method, without retrospectively obtaining 272 
definitive diagnoses, which were not possible given data anonymization and ethical considerations.  273 
Different practices, and veterinarians working ‘in the field’ as opposed to a hospital setting, will have 274 
employed differing diagnostic modalities in laminitis case investigation.  We posit, however, that a 275 
diagnosis of laminitis made through clinical examination and radiography alone is likely to be 276 
sufficiently accurate (given that this will be the basis for treatment in a great many animals) to allow 277 
case identification in this study.  Therefore, although other diagnostic investigations would offer 278 
more information on the disease course, the diagnosis without such information is valid and worthy 279 
of inclusion.  Most clinical scenarios were grouped into ‘syndromes’ for use here, to enable inclusion 280 
of clinical signs likely to lead to corticosteroid administration before definitive diagnoses were 281 
reached.  Given these differences, apparent disease prevalence reported here cannot be directly 282 
compared to other studies.  No husbandry or environmental details were included in EMR, therefore 283 
known laminitis risk factors related to, for example, grain overload, could not be included in the 284 
models.  Some errors were detected in either the date of veterinary care episode, or date of birth of 285 
some horses (16% of records).  It was not possible to identify which dates were erroneous, therefore 286 
calculated ages with spurious values were set as missing.  We had no reason to believe that date 287 
errors would systematically over or underestimate horse ages, and had no way of retrospectively 288 
validating dates resulting in appropriate ages, therefore age was included in the analyses, but 289 
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conclusions drawn from it must be interpreted cautiously.  Horses were anonymised and given a 290 
unique numeric identifier before analyses proceeded.  Given that registration at multiple veterinary 291 
practices is possible, some duplication or truncation of medical histories may have occurred, but 292 
given the geographic spread of the practices involved this was thought likely to be minimal.  For 293 
similar reasons, laminitis or other disease diagnoses (or corticosteroid administration) may have 294 
occurred prior to an animal’s inclusion in these data.  All horses were considered at risk of laminitis, 295 
provided it was more than sixty days since their last episode.  This time period was chosen as it was 296 
thought likely that a horse suffering an active episode of laminitis would receive veterinary products 297 
or attention at least once in a two-month period.  There are no previous studies from which to 298 
validate this assumption, however, therefore it may be an over or underestimate.  EMS, PPID and 299 
RAO are lifelong conditions known to increase laminitis risk (McCue et al., 2015; Menzies-Gow, 2015; 300 
Tadros and Frank, 2013).  Horses with these diagnoses may, therefore, have been under greater 301 
scrutiny for signs of laminitis, and apparent prevalence may therefore have been inflated in these 302 
animals.  Changes over the study period in the prevalence of diagnosis of each condition should not 303 
have materially affected the estimates of strength of association with laminitis due to the nature of 304 
survival analysis. 305 
 306 
The clinical syndromes tested for association with laminitis in this study represent many of the 307 
clinical scenarios encountered in primary practice, that are either known or thought to pose an 308 
increased risk of laminitis (e.g. endometritis), or are indications for the use of corticosteroids.  309 
Without inclusion of the possible causes of corticosteroid use, spurious associations between drug 310 
use and laminitis may have been generated.  Despite the inclusive, general terms used to categorise 311 
EMR, inclusion of disease syndromes led to corticosteroid use dropping out of significance in most 312 
multivariable models.  Respiratory syndromes and RAO were included as separate risk factors in this 313 
study.  Corticosteroids are often administered to ease inflammation-related respiratory clinical signs 314 
in the absence of definitive diagnoses.  Respiratory signs such as cough, dyspnoea and wheezing can 315 
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be associated with multiple diseases.  RAO represents a specific clinical entity, which theoretically 316 
poses a lifelong risk of laminitis due to its corticosteroid-based treatments, or possibly due to the 317 
effects systemic inflammation (Cornelisse and Robinson, 2013; Menzies-Gow, 2015).  RAO was 318 
included separately so that, as with PPID and EMS, diagnosis of these conditions would render an 319 
animal permanently categorised as suffering from that condition, unlike other transient, curable 320 
respiratory conditions.  The Cramer’s V statistic for association between respiratory and RAO 321 
categories was 0.09 (data not shown), indicating sufficiently low association to include both as 322 
independent predictors. 323 
 324 
Four corticosteroid drugs were included in these analyses, due to their commonness in practice and 325 
their systemic or intra-synovial routes of administration.  These four drugs have been found to exert 326 
different effects upon equine tissues, have different pharmacologic properties, and could therefore 327 
be supposed to have different associations (if any) with laminitis risk(Cornelisse and Robinson, 2013; 328 
McIlwraith, 2010).  Specific drug formulations were not always included in EMR, and accurate doses 329 
and anatomic sites of administration were vanishingly rare.  Most horses in the primary care setting 330 
are not weighed regularly, and drug dosing tends to be calculated based on the veterinarian’s best 331 
guess of an animal’s weight.  Therefore, given the paucity of accurate information available, drug 332 
dose was not included in these analyses.  Only the use of prednisolone remained in the multivariable 333 
Model 2 after accounting for significant signalment and clinical parameters.  This suggests that 334 
triamcinolone, dexamethasone and methylprednisolone, used as they were in this population over 335 
the study period, do not pose a risk of laminitis induction or recurrence.  The reason for this 336 
difference is unclear, however it may relate to the differences in route of administration; 337 
prednisolone is often administered orally in tablet form (Peroni et al., 2002), whereas the other 338 
corticosteroids are more commonly delivered via intra-muscular injection.  A course of prednisolone 339 
tablets would therefore represent a single prescription, but a much longer exposure time (through 340 
multiple doses) compared to single injections.  Although the potency of triamcinolone and 341 
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dexamethasone may be greater than the equivalent dose of prednisolone (Johnson et al., 2002), 342 
given this postulated difference in exposure time, the risk of laminitis following prednisolone 343 
administration would be magnified.  It is possible that the ‘true’ magnitude of effect of 344 
triamcinolone and dexamethasone on laminitis risk is significant (i.e. over 1), but this study would 345 
have been underpowered to detect associations of less than 1.3 using the Cox proportional hazard 346 
model.   347 
 348 
Clinical risk factors for initial laminitis episodes were found to differ from those for subsequent 349 
episodes.  Only PPID, orthopaedic, systemic and respiratory syndromes were found to be associated 350 
with time to laminitis episode in both scenarios.  Interestingly, RAO appeared to be associated with 351 
an increased risk of the initial laminitis episode, but a reduced risk of subsequent episodes.  The 352 
reason for this disparity is not known.  Breed and sex were important risk factors for initial laminitis 353 
episode, but not for subsequent episodes.  Both breed and sex have previously been associated with 354 
laminitis risk (Alford et al., 2001; Bamford et al., 2014; Wylie et al., 2014), as have the 355 
endocrinopathies PPID and EMS (Donaldson et al., 2004; Johnson et al., 2002; C. E. Wylie et al., 356 
2013).  Many significant interaction terms were included in both final multivariable models.  These 357 
terms were not shared between both models, but all included either PPID, EMS or RAO, which were 358 
included as lifelong diagnoses after the initial diagnostic record.  All main effects remained 359 
statistically significant despite the inclusion of interactions.  Interplay between clinical risk factors for 360 
laminitis is therefore very complex.  Categories of clinical signs included as predictors in these 361 
analyses were intended to capture potential associations between underlying (unknown) disease 362 
processes and laminitis, to avoid spurious associations of drug administration with the outcome.  363 
Therefore, greater emphasis should be placed on interpreting the presence or absence of 364 
corticosteroid administration predictors in final models, rather than the presence, or magnitude of 365 
clinical sign risk factors.  The only truly putative risk factor with a significant laminitis risk association 366 
in these models was prednisolone administration.  This corticosteroid should therefore be avoided in 367 
24 
 
horses with pre-existing laminitis risks or those who have already suffered from the disease.  Good 368 
management may lower the risk of EMS (through maintenance of appropriate weight), dermatologic 369 
syndromes (via avoidance of injuries leading to cellulitis, for example), or colic, but for the most part, 370 
these clinical conditions are unavoidable.  It was beyond the scope of this study to assess the effects 371 
and appropriateness of treatment of the conditions included on laminitis risk, but future research 372 
may be able to ascertain which treatment regimens can modify the disease course and offer hope of 373 
avoiding future laminitis episodes.  Similarly, we did not include information on the treatment of 374 
laminitis (e.g. orthopaedic shoeing, corrective farriery, nutritional adjustment, rest periods etc.) as it 375 
was beyond the scope of this study, and in many cases was not recorded.  Many of these factors 376 
could have modified the likelihood and time to subsequent laminitis episodes following the first 377 
diagnosis, however there was no reason to presume systematic differences in laminitis treatment 378 
between the categories of independent variables included. 379 
 380 
The use of equine first-opinion EMR for studies of this type is feasible, and offers advantages over 381 
smaller scale, prospective studies, or those involving only referral populations.  It does, however, 382 
pose additional challenges and has some limitations which need to be addressed and taken into 383 
account if study validity is to be accepted.  Data errors can be a feature of any study, but are difficult 384 
or impossible to rectify.  The variable nature of medical records also means that useful information is 385 
often missing, either systematically (like horse weights), or idiosyncratically. Studies focusing on 386 
prescription information may offer the most accuracy in terms of sensitivity of categorisation, due to 387 
the automated nature of prescribing and billing, but will likely always suffer from a lack of dosing 388 
information in this species until weighing horses accurately becomes easy and commonplace.  389 
Despite these limitations, EMR can be used to better understand veterinary decision-making, and to 390 
help untangle complicated disease systems that require large sample sizes for their estimation. 391 
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